輪證日報|東嶽集團業績預喜,牛證漲60%
今日市場短評
港股收盤,恆指小幅收漲0.3%,恆生科技指數收漲0.82%,特斯拉概念股、醫藥外包概念股、黃金股造好,物管股、芯片股走低。
窩輪(認股證)焦點
藥明生物(02269)
藥明認購證(19532)到期日:2022年6月
槓桿:5.34倍
醫藥外包板塊午後漲幅擴大 近日獲美國資本集團增持超3億 獲北水累計增持超22億
消息面上,港交所權益資料顯示,2月11日,藥明生物獲美國資本集團增持553.63萬股,每股平均價56.077港元,涉資約3.1億港元。增持後,美國資本集團的最新持股數目爲2.97億股,持股比例由6.92%增持至7.05%。此外,藥明生物獲北水資金連續5天淨買入,累計淨買入金額22.04億港元。
浙商證券認爲,CXO板塊在此前的持續下跌後,估值底部逐步顯現,目前CXO板塊普遍處於歷史估值底部,在外部利好催化不斷,內部經營質量和海外大客戶認可度持續提升前景下,看好CXO行情。
牛熊證焦點
東嶽集團(00189)
東嶽牛證(59711)到期日:2023年2月
回收價:8.38槓桿:3.59倍
東嶽集團拉昇10% PVDF行業繼續擴產,公司業績大幅預喜
近期,PVDF相關海內外企業不斷傳出產能擴建消息,機構建議關注已有PVDF產能及原材料優勢的公司。東嶽集團發佈兩份業績預喜公告,顯示去年淨利將實現大增。截至發稿,東嶽集團漲9.78%,報10.10港元,成交額1.40億港元。
此前,東嶽集團發佈業績預喜公告,預期去年公司擁有人應佔淨溢利將取得大幅增長。而公司旗下有機硅平臺東嶽硅材同樣發佈預喜公告,指去年實現扣非淨利潤10.14億元—12.90億元,同比增長304.09%—414.19%。
東嶽集團主營包括高分子(PTFE、PVDF)、有機硅、製冷劑三大業務板塊。其中,有關PVDF的產能和價格成爲市場關注的焦點。
衍生品資金流入/流出


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.